Market Place
Sourcing Support
Phase 3 Data at AAD 2023 Show Deuruxolitinib Improved Scalp Hair Regrowth
18 Mar 2023 //
PR NEWSWIRE
Sun Pharma Completes Acquisition of Concert Pharmaceuticals
07 Mar 2023 //
PR NEWSWIRE
Concert Maintains Deuruxolitinib Breakthrough Therapy Designation from FDA
15 Feb 2023 //
BUSINESSWIRE
Concert persuades FDA to keep alopecia therapy breakthrough tag
15 Feb 2023 //
FIERCE BIOTECH
India`s Sun Pharma acquires U.S. based Concert for $576 mln
20 Jan 2023 //
REUTERS
Concert Announces Presentation of Deuruxolitinib THRIVE-AA1 PIII Study Results
21 Nov 2022 //
BUSINESSWIRE
Concert to Participate in Fireside Chat at the Jefferies London Conference
09 Nov 2022 //
BUSINESSWIRE
Concert Pharmaceuticals Reports Third Quarter 2022 Financial Results
07 Nov 2022 //
BUSINESSWIRE
Concert Pharmaceuticals to Report Third Quarter 2022 Results on November 7, 2022
31 Oct 2022 //
BUSINESSWIRE
Concert Pharmaceuticals Announces Presentation of CTP-543 THRIVE-AA1 PIII Data
10 Sep 2022 //
BUSINESSWIRE
Illuminated blue buildings bring attention to alopecia areata
07 Sep 2022 //
FIERCEPHARMA
Concert Pharma to Present at H.C. Wainwright Global Investment Conference
06 Sep 2022 //
BUSINESSWIRE
Concert Pharma`s Exercise of Warrants Under Existing Financing Arrangement
22 Aug 2022 //
BUSINESSWIRE
Concert Pharma Announces That Results From CTP-543 THRIVE?AA1 Phase 3 Trial
22 Aug 2022 //
BUSINESSWIRE
Concert Pharmaceuticals Reports Second Quarter 2022 Financial Results
04 Aug 2022 //
BUSINESSWIRE
Concert says second late-stage study for hair loss therapy reached main goal
02 Aug 2022 //
SEEKING ALPHA
Concert Pharma Reports Positive Results for 2nd CTP?543 PIII Clinical Trial
01 Aug 2022 //
BUSINESSWIRE
Concert Pharmaceuticals to Report Second Quarter 2022 Results on August 4, 2022
29 Jul 2022 //
BUSINESSWIRE
Concert Pharma to Participate in Fireside Chat at The JMP Securities Conference
09 Jun 2022 //
BUSINESSWIRE
PII Dose Ranging Trial Results Of CTP 543 In Alopecia Published In AAD Journal
07 Jun 2022 //
PRESS RELEASE
Concert Pharma Raises Gross Proceeds of $66.4M Through Public Offering
06 Jun 2022 //
BUSINESSWIRE
Concert Pharmaceuticals Announces Pricing of Public Offering
01 Jun 2022 //
BUSINESSWIRE
Concert Pharmaceuticals Announces Proposed Public Offering of Common Stock
31 May 2022 //
BUSINESSWIRE
Concert Pharmaceuticals tunes up PhIII win for alopecia drug
24 May 2022 //
ENDPTS
Concert Pharmaceuticals Reports First Quarter 2022 Financial Results
05 May 2022 //
BUSINESSWIRE
Concert Pharmaceuticals to Report First Quarter 2022 Results on May 5, 2022
28 Apr 2022 //
BUSINESSWIRE
Terran acquires Concert`s CNS pipeline
12 Mar 2022 //
PRNEWSWIRE
Concert Pharma Reports 2021 Financial Results and Provides Company Update
03 Mar 2022 //
BUSINESSWIRE
Concert Pharmaceuticals to Report Fourth Quarter 2021 Results on March 3, 2022
24 Feb 2022 //
BUSINESSWIRE
Concert Pharma Completes Enrollment in Phase 3 Trial Evaluating CTP-543
04 Jan 2022 //
BUSINESSWIRE
Concert Reports Q3 2021 Financial Results and Provides Company Update
09 Nov 2021 //
BUSINESSWIRE
Concert Pharmaceuticals Completes Enrollment in THRIVE-AA1 Ph3 CTP-543
25 Oct 2021 //
BUSINESSWIRE
Concert Pharmaceuticals to Present at Upcoming Investor Conferences
03 Sep 2021 //
BUSINESSWIRE
Concert Pharmaceuticals to Present at Upcoming Investor Conferences
03 Sep 2021 //
BUSINESSWIRE
Concert Pharmaceuticals Reports Second Quarter 2021 Financial Results
05 Aug 2021 //
BUSINESSWIRE
Concert Pharmaceuticals to Report Second Quarter 2021 Results on August 5, 2021
29 Jul 2021 //
BUSINESSWIRE
Concert Pharma Presents Update on CTP-543 Long-Term Extension Study
01 Jul 2021 //
BUSINESSWIRE
Concert Initiates THRIVE-AA2 Phase 3 Clinical Trial Evaluating CTP-543
27 May 2021 //
BUSINESSWIRE
Concert Initiates THRIVE-AA2 Phase 3 Clinical CTP-543 for Alopecia Areata
27 May 2021 //
BUSINESSWIRE
Concert Announces Sale of VX-561 Milestones to Vertex for $32 Million
17 May 2021 //
BUSINESSWIRE
Concert Pharmaceuticals Announces Sale of VX-561 Milestones to Vertex
17 May 2021 //
BUSINESSWIRE
Concert Pharmaceuticals Reports First Quarter 2021 Financial Results
04 May 2021 //
BUSINESSWIRE
Concert’s schizophrenia treatment trial fails to meet endpoints
02 Feb 2021 //
CLINICALTRIALSARENA
Concert Announces Results from CTP-692 Ph2 Trial in Patients with Schizophrenia
01 Feb 2021 //
BUSINESSWIRE
Concert crushed on PhII schizophrenia flop; Amgen`s sotorasib gets BTD in China
01 Feb 2021 //
ENDPTS
Concert dumps schizophrenia drug CTP-692 after failing phase 2
01 Feb 2021 //
FIERCE BIOTECH
Concert Initiates THRIVE-AA1 Phase 3 Clinical Trial Evaluating CTP-543
03 Nov 2020 //
BUSINESSWIRE
Concert Initiates THRIVE-AA1 Ph3 Clinical Trial Evaluating CTP-543
03 Nov 2020 //
BUSINESSWIRE
Concert Pharmaceuticals Presents CTP-543 Data from Long-Term Extension Study
29 Oct 2020 //
BIOSPACE
Concert Presents CTP-543 Data from Long-Term Extension Study in Alopecia
29 Oct 2020 //
BUSINESSWIRE
Concert Pharmaceuticals Announces CTP-543 Alopecia Areata Data Selected
12 Oct 2020 //
BUSINESSWIRE
Concert gets BTD for alopecia drug, setting up a late-stage showdown with Pfizer
09 Jul 2020 //
ENDPTS
Concert Pharmaceutical Receives FDA Breakthrough Therapy Designation for CTP-543
08 Jul 2020 //
BUSINESSWIRE
Concert Pharma Releases Additional Data from Ph 2 Clinical Trial of CTP-543
12 Jun 2020 //
BUSINESSWIRE
Concert Pharma Releases Additional Data from Phase 2 Clinical Trial of CTP-543
12 Jun 2020 //
BUSINESSWIRE
Concert Announces Plans for CTP-543 Phase 3 Trials in Alopecia Areata
01 Apr 2020 //
BUSINESSWIRE
Concert Pharmaceuticals Announces Plans for CTP-543 Phase 3 Trials
01 Apr 2020 //
BUSINESSWIRE
Concert Pharmaceuticals Selected for Late-Breaking Oral Presentation of CTP-543
24 Feb 2020 //
BUSINESSWIRE
Sanofi/Regeneron Dupixent; Alkermes` antipsychotic get dates with the FDA
28 Jan 2020 //
ENDPTS
Concert Announces Federal Circuit Granted its Motion Involving CTP-543
27 Jan 2020 //
GLOBENEWSWIRE
